Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
41st Annual Miami Breast Cancer Conference®
View More
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
7th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards
View More
3rd Annual International Congress on the Future of Women’s Health™
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
The 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
Epcoritamab Obtains Accelerated Approval for Relapsed/Refractory DLBCL
May 19th 2023The FDA has granted epcoritamab accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. The prescribing label comes with boxed warnings for cytokine release syndrome and neurologic problems.